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Introduction
Cigarette  smoking  is  the  largest  preventable  cause  of 
morbidity  and  mortality  in  the  world.  Despite  best 
available treatments, smoking cessation remains an elusive 
goal for most smokers and relapse is normal. Cigarette 
smoking behavior is influenced, in part, by genetic factors 
[1].  Incorporating  smoking-related  genetic  risk  infor-
mation into clinical practice has the potential to increase 
smoking cessation rates and improve public health. Here, 
we discuss the clinical implications of emerging findings 
from  genome-wide  association  studies  (GWASs)  for 
smoking behavior and pharmacogenetic trials of cessa-
tion treatments. We suggest that research from multiple 
disciplines should be conducted in parallel to bring us 
closer  to  the  goal  of  delivering  personalized  cessation 
treatment for smokers.
GWASs of smoking behavior
Since 2007, several GWASs among individuals of Euro-
pean ancestry have been conducted for different smoking 
phenotypes,  including  smoking  initiation  (ever  versus 
never  smokers),  age  of  smoking  initiation,  number  of 
cigarettes  smoked  per  day  (CPD),  nicotine  dependence 
(based  on  the  Fagerström  test  for  nicotine  dependence 
score), smoking cessation (former versus current smokers), 
pack-years and duration of smoking (see Supplementary 
Table  1  in  [2]).  Most  recently,  meta-analyses  were  con-
ducted among 143,023 individuals of European ancestry 
[2-4].  Remarkably,  whereas  previous  GWASs  for  other 
complex traits with far smaller sample sizes had discovered 
multiple novel variants, only one locus on chromosome 
15,  which  harbors  the  cluster  of  nicotinic  acetylcholine 
receptor  genes  CHRNA3-CHRNA5-CHRNB4,  has  been 
robustly associated with CPD across multiple GWAS of 
smoking [2-7]. The single nucleotide polymorphism (SNP) 
rs1051730 was identified as being most strongly associated 
with CPD; each copy of the variant allele (allele frequency = 
0.35) was estimated to increase smoking by approximately 
one cigarette per day and accounted for only 0.5% of the 
variance in CPD [2].
The  statistical  power  bestowed  by  the  tremendous 
sample  sizes  of  the  GWAS  meta-analyses  for  smoking 
effectively exclude the potential of identifying large effects 
(>1.5)  for  common  allele  frequencies  represented  on 
current GWAS chips. However, additional loci for smoking 
behavior  can  be  identified  as  a  result  of  the  improved 
genomic coverage of newer GWAS chips and by analyses 
of the 1000 Genomes project, which will enable an exten-
sion of systematic GWAS methods to SNPs with 1 to 5% 
allele  frequencies  [8].  In  addition,  future  GWASs  that 
refine phenotypic characterization of cessation by incor-
porating  longitudinal  data  on  prospective  quit  attempts 
and  relapses  among  smokers  may  reveal  loci  associated 
with  quitting  smoking.  Algorithms  that  incorporate 
multiple risk variants and their interactions also may yield 
stronger associations for different smoking behaviors.
Clinical validity of GWAS findings for smoking
Because of their low penetrance and inability to explain 
more  than  a  small  fraction  of  observed  heritability, 
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regarded as lacking sufficient sensitivity, specificity and 
predictive value to serve as clinical markers of heightened 
risk of nicotine dependence and persistent smoking in 
the general population [9]. To translate into a clinically 
valid marker, a risk factor has to be very strongly asso-
ciated with a trait. Ware [10] demonstrated that even a 
marker with an odds ratio as high as 3.58 will not perform 
well as a predictive test for individual patients. Although 
we evaluated CPD as a quantitative variable in the GWAS 
meta-analysis [2], the observed effect size was not suffi   -
ciently large. Furthermore, whether the SNPs identified 
in GWASs for CPD are relevant for cessation is unclear. 
Although there seems to be partial overlap between some 
genomic regions associated with CPD and cessation [11], 
SNPs in CHRNA3-CHRNA5-CHRNB4 have not been asso-
ciated with smoking cessation in previous GWASs [2-4].
The effect sizes of SNPs on smoking behaviors may be 
larger in the context of gene-environment interactions in 
therapeutic  clinical  trials  (pharmacogenetics)  [12]. 
Pharmacogenetic studies of smoking cessation therapies 
may  help  identify  subgroups  of  smokers  who  respond 
more favorably to specific treatments and help determine 
their  optimal  dose  and  duration  of  treatment.  So  far, 
pharmacogenetic trials of smoking cessation suggest that 
genetic variation in nicotine metabolizing enzymes and 
dopamine and opioid pathways may have a role in the 
efficacy of nicotine replacement therapy (NRT), whereas 
variation in the dopamine pathway may be relevant for 
response to the smoking cessation drug bupropion [13].
GWASs in pharmacogenetic studies
In  pharmacogenetic  studies,  GWASs  may  have  even 
greater potential to identify loci associated with improved 
cessation and, in particular, rare adverse events [12,14]. 
Preliminary  evidence  from  the  first  pharmacogenetic 
GWAS of smoking cessation [15] suggests that regions 
associated  with  successful  abstinence  on  bupropion  or 
NRT  are  not  identical,  supporting  observations  from 
candidate gene pharmacogenetic studies discussed above 
[13],  but  replication  is  required.  Given  the  rare  but 
serious potential psychiatric side-effects of non-nicotinic 
pharmacotherapies [16], GWASs of bupropion and other 
therapies, such as varenicline, are warranted.
Future directions
Clearly, changes in public policy, including indoor air acts, 
increased taxes on cigarettes and bans on tobacco product 
advertising, have contributed significantly to a decrease in 
smoking prevalence in the US [17]. However, given that 
the prevalence of current smokers seems to be stabilizing, 
and existing cessation treatments help only a fraction of 
smokers to quit, new tailored approaches for cessation that 
involve insights from genetics deserve to be considered.
Although  substantial  progress  has  been  made  in  the 
genetics  of  smoking  in  recent  years,  more  research  is 
needed.  To  maximize  the  potential  for  personalized 
treat  ment  for  smokers,  translational  research  from 
multiple disciplines should be conducted in parallel with 
ongoing  GWASs  for  smoking  behavior  and  pharmaco-
genetic studies of smoking cessation. Behavioral research 
on  the  uptake,  understanding  and  consequences  of 
genetic risk communication will increase the likelihood 
that future genetic testing of smoking will result in public 
health improvements [18] and reduce the likelihood of 
harm;  such  harm  could  include  a  lowering  of  the 
motivation to quit or of the self-efficacy for quitting, both 
of  which  could  undermine  quitting  efforts.  Research 
surrounding the ethical, legal and social implications of 
genetic research on smoking [19] will help us handle the 
potential  discrimination  against  patients  related  to 
inappropriate use of their genetic information, given the 
known co-morbidity between nicotine dependence and 
other  substance  abuse  conditions  and  psychiatric  dis-
orders, the possibility of pleiotropic associations and the 
differential  prevalence  of  risk-conferring  genotypes 
among  different  ancestries.  Cost-benefit  analyses  of 
genetically tailored treatment for smoking will contribute 
to  the  feasibility  of  these  approaches.  Finally,  develop-
ment  of  genetic  testing  guidelines  for  and  training  of 
health care providers is needed to standardize care and 
increase their confidence in interpreting and conveying 
results to their patients [20].
The coordinated effort of multidisciplinary research teams 
that  address  these  complex  issues  will  help  inform  the 
circumstances under which we can translate the genetics of 
smoking into clinical practice in the hope of reducing the 
burden  of  smoking  in  our  society.  Until  the  goal  of 
personalized  cessation  treatment  is  realized,  all  smokers 
should be encouraged to quit, regardless of genotype.
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